Reversal of Prasugrel in Bleeding or Urgent Surgery
Discontinuation Strategy for Planned Surgery
- The American College of Cardiology recommends discontinuing prasugrel at least 7 days before any surgery to allow dissipation of antiplatelet effects 1, 2, 3, 4
- For intracranial surgery specifically, the American College of Cardiology adds 2 additional days (total 9 days) to the discontinuation period 6, 7
- The 7-day window reflects prasugrel's irreversible platelet inhibition lasting the platelet lifespan (7-10 days) 8
Management of Active Bleeding
- The American Society of Anesthesiologists prioritizes mechanical hemostasis (surgery, endoscopy, embolization, tamponade) over drug discontinuation in cases of active bleeding 6, 7
- The American Society of Anesthesiologists recommends administering tranexamic acid early in severe bleeding - safe and effective without increased thrombotic risk 6, 7, 9
- Platelet transfusion for prasugrel reversal should be at least double the standard dose used for aspirin reversal (>1.0-1.4 × 10¹¹ platelets per 10 kg body weight) 9
- Recombinant Factor VIIa (rFVIIa) is not recommended for prasugrel reversal due to no demonstrated hemostatic benefit and potential to induce arterial thrombosis 9
Procedure-Specific Considerations
- For non-neurosurgical urgent/immediate procedures, the American Society of Anesthesiologists recommends proceeding without neutralization if the patient is on prasugrel monotherapy 6, 7
- In cases of intracranial hemorrhage, the American Society of Anesthesiologists recommends neutralizing antiplatelet therapy before urgent or immediate intracranial surgery 6, 7, 9
- Early platelet transfusion (within 12 hours) is associated with less hematoma expansion in cases of intracranial hemorrhage 6, 7